The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiomic features for patients with primary soft tissue sarcomas: A prognostic study.
 
Sandro Pasquali
No Relationships to Disclose
 
Marco Bologna
No Relationships to Disclose
 
Gabriele Infante
No Relationships to Disclose
 
Raffaella Vigorito
No Relationships to Disclose
 
Antonella Messina
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Rosalba Miceli
No Relationships to Disclose
 
Gabriella Greco
No Relationships to Disclose
 
Alessandra Casale
No Relationships to Disclose
 
Valentina Corino
No Relationships to Disclose
 
Francesco Barretta
No Relationships to Disclose
 
Luca Mainardi
No Relationships to Disclose
 
Elena Palassini
No Relationships to Disclose
 
Roberta Sanfilippo
Honoraria - Lilly; PharmaMar
Consulting or Advisory Role - Lilly
Research Funding - Amgen/Dompé; Bayer; Dômes Pharma; Epizyme; Novartis; PharmaMar
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Paolo Giovanni Casali
Consulting or Advisory Role - Bayer; Deciphera
Speakers' Bureau - Pfizer
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
 
Dario Callegaro
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar